Web11 May 2024 · Tenaya Therapeutics today provided business and program updates, and reported financial results for the first quarter ended March 31, 2024. ... TN-201 Received … Web11 Jan 2024 · Shares of Tenaya Therapeutics, Inc. are down 85% from their IPO pricing in July 2024. Click here to read my analysis of TNYA stock. ... For TN-201 we estimate …
Tenaya Therapeutics to Participate in Inaugural Hypertrophic ...
Web9 Apr 2024 · Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Rating) has earned an average rating of "Buy" from the six brokerages that are presently covering the company, MarketBeat Ratings reports. ... and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic ... Web14 Apr 2024 · Tenaya Therapeutics has a 1-year low of $1.64 and a 1-year high of $11.86. The stock has a market capitalization of $201.92 million, a P/E ratio of -1.08 and a beta of 2.22. About Tenaya Therapeutics . Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. strawberry frappe mix
Tenaya Therapeutics Stock Price Today (NASDAQ: TNYA) Quote, …
Web31 Dec 2024 · Tenaya’s most advanced candidates include TN-201, a gene therapy for MYBPC3- associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2 -associated arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301, a small molecule HDAC6 inhibitor being initially developed for heart failure with preserved ejection … WebTenaya Therapeutics. May 2024 - Present2 years. South San Francisco, California, United States. Currently researching and developing cardiovascular AAV-based gene therapy platforms for ... WebTenaya Therapeutics 13,806 followers 1y Report this post Report Report. Back ... round scratch pad refill